Impact of Chemotherapy on Ovarian Reserve in Young Women With Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 250
- 试验地点
- 11
- 主要终点
- To evaluate the effects of adjuvant or neoadjuvant chemotherapy treatment on ovarian reserve for in situ breast cancer patients
研究概览
简要总结
The aim of this protocol is to study the deleterious impact of adjuvant chemotherapy or neoadjuvant chemotherapy on ovarian reserve in young women suffering from breast cancer. A new relevant ovarian reserve marker, serum Anti-Mullerian Hormone, will be used in order to evaluate precisely the impact of chemotherapy on ovaries during chemotherapy administrations and after during follow-up (24 months). This strategy offers 2 main advantages : no modification of the traditional care of patients (treatment, organisation, follow up ...) and use of a non invasive marker (serum). The final objective is to give precise information to patients on their future fertility after remission.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 39 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •female 18-39 years
- •suffering from breast cancer
- •treated with adjuvant or neoadjuvant chemotherapy
排除标准
- 未提供
结局指标
主要结局
To evaluate the effects of adjuvant or neoadjuvant chemotherapy treatment on ovarian reserve for in situ breast cancer patients
时间窗: 24 months
Serum anti-Müllerian hormone concentration will be measured at each chemotherapy administration and 24 months follow-up after chemotherapy completion
次要结局
未报告次要终点